Compassionate Care ALS takes a comprehensive approach to integrating our CARE with research institutions, ALS clinics and hospitals. We work to ensure appropriate care and education for those individuals and families who are newly diagnosed as well as those currently enrolled in clinical trials. We also provide information to those interested in existing trials and those who wish to be informed about research efforts. We work with our current clients to connect them with clinical trials at ALS ONE partner organizations.
For clinical trials occurring at our ALS ONE partners, Massachusetts General Hospital, ALS TDI and UMass Medical Center we offer our families along with ALS ONE partner families rides to trials in our handicapped accessible vans. For more information about our transportation program, please contact Shannon Carey at Shannon@ccals.org or (508) 444-6775.
Neurological Clinical Research Institute (NCRI) MGH is proud to be a part of the ALS ONE partnership, providing innovative care and performing pioneering research to cure ALS. Our clinical and research programs are tightly aligned and synergistic.
The mission of the MGH multidisciplinary ALS clinic is to be a place of caring and hope. It is where we lay the foundation for a partnership between providers, researchers, people with ALS and their caregivers and loved ones. And, together, through care, we seek a cure. The mission of our research institute, the MGH NCRI, is to translate scientific discovery into new ALS therapies as rapidly as possible. Here, we bring potential therapies to research participants and collaborate with researchers around the world to seek novel avenues to a cure. For information about clinical trials please visit www.massgeneral.org/clinicaltrials. Or contact Access Nurse, Katie Tee (617) 643-6249 or firstname.lastname@example.org.
UMass Medical School offers the latest in research and clinical trials. Patients benefit from advanced diagnostic and treatment options that come from this research. Learn more about basic and clinical research at UMMS.
See more at www.umassmedresearchvolunteer.org/clinical_studies_conditions_list.aspx. Or contact Diane McKenna-Yasek at (508) 856-4697.
The ALS Therapy Development Institute operates the world’s first and largest precision medicine program in ALS. The goal of the program is to identify subtypes of ALS and the specific compounds that treat each type to advance the most effective treatments into clinical trial.